1[1]Gales AC, Jones RN, Turnidge J, et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999[J].Cin Infect Dis, 2001, 32(Suppl 2): S146-155
2[2]Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones[J]. Clin Infect Dis, 2001, 32(Suppl 1): S9-S15
3[3]Ball P. Quinolone generations: natural history or natural selection?[J] J Antimicrob Chemother, 2000, 46(Suppl T1): 17-24
4[4]Heddle JG, Barnard FM, Wentzell LM, et al. The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action [J]. Nucleosides Nucleotides Nucleic Acids,2000, 19:1249-1264
5[5]Jalal S, Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa[J]. Microb Drug Resist,1998, 4:257-261
6[6]Yonezawa M, Takahata M, Matsubara N, et al. DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother , 1995,39: 1970-1972
7[7]Nakano M, Deguchi T, Kawamura T, et al. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother,1997, 41: 2289-2291
8[8]Shen LL. Quinolone interactions with DNA and DNA gyrase [J]. Methods Mol Biol , 2001, 95:171-184
8Kapranov Ni, Shatalova LA, Kashirakaia NI, et al. Antibiotic therapy of cystic fibrosis in children[J]. Antibiot Khimioter, 2001,46(2): 26-32.
9Van Eldere J. Muhicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections[J]. Antimicrobial Chemotherapy, 2003, 51:347 -352.
10Magee JT, Pritchard EL, Fitigerald KA, et al. Antibiotic preacribing and antibiotic resistance in community practice: retrospective study, 1996- 1998[J]. British Medical Joural 1999, 319(6): 1 238 - 1 241.
